(CGEN) Compugen - Ratings and Ratios

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery and development company specializing in immuno-oncology. The company focuses on developing novel cancer treatments through its pipeline, which includes COM701, an anti-PVRIG antibody in Phase 1 trials for solid tumors; COM902, an anti-TIGIT antibody also in Phase 1; Bapotulimab, targeting ILDR2 in Phase 1 for head and neck cancer; and Rilvegostomig, a bispecific anti-TIGIT/PD-1 antibody in Phase 3 for non-small cell lung cancer. Their preclinical programs address immune resistance mechanisms, including COM503, which blocks IL-18 binding protein interaction. Compugen collaborates with major pharmaceutical companies like Bristol-Myers Squibb, AstraZeneca, and Gilead, leveraging their expertise in bispecific antibodies and immune modulation. Headquartered in Holon, Israel, Compugen was founded in 1993 and is listed on the NASDAQ.

Compugens business model emphasizes partnerships and licensing agreements, enhancing their research and development capabilities. Their focus on bispecific antibodies underscores their commitment to innovative cancer treatments, aiming to overcome resistance mechanisms and improve patient outcomes. The companys approach aligns with the broader biotech industrys trend towards collaborative drug development.